baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Call 210 PGR 21.02.2025/ DE000JT2UTX3 /

2024-06-28 10:26:42 AM	Chg.+0.10	Bid10:00:41 PM	Ask10:00:41 PM	Underlying	Strike price	Expiration date	Option type
2.41EUR	+4.33%	- Bid Size: -	- Ask Size: -	Progressive Corporat...	210.00 USD	2025-02-21	Call

GlobeNewswire 06-25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...

GlobeNewswire 06-25 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial

GlobeNewswire 06-24 Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...

GlobeNewswire 06-24 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...

GlobeNewswire 06-24 Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...

GlobeNewswire 06-19 Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

GlobeNewswire 06-18 Afamelanotide in fair-skinned Parkinson’s patients

GlobeNewswire 06-14 Progressive Reports May 2024 Results

GlobeNewswire 06-13 Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...

GlobeNewswire 06-12 Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...

GlobeNewswire 06-12 Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...

GlobeNewswire 06-11 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...

GlobeNewswire 06-11 Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...

GlobeNewswire 06-11 FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...

GlobeNewswire 06-10 LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...

GlobeNewswire 06-10 SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in...

TeleTrader 06-09 EP updated results, EPP with 189 seats

TeleTrader 06-09 EPP's Weber claims party victory in EP election

GlobeNewswire 06-07 TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 06-07 Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...

GlobeNewswire 06-06 Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple...

GlobeNewswire 06-06 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Mo...

GlobeNewswire 06-05 The Alignment Studio Physiotherapy Melbourne Celebrates Receiving Only 5-Star Reviews Since Opening

GlobeNewswire 06-05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Preventio...

GlobeNewswire 06-05 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...

JP Morgan Call 210 PGR 21.02.2025/ DE000JT2UTX3 /

If you wish to receive reply to your feedback, please provide your email address.